Clinical trials
Phase 2 Scleroderma, Diffuse trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
39 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2006 | 2 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 2 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
| Terminated | 7 |
| Recruiting | 6 |
| Active, not recruiting | 5 |
| Withdrawn | 3 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 3 |
| Dinesh Khanna, MD, MS | 2 |
| Johns Hopkins University | 2 |
| Kadmon, a Sanofi Company | 2 |
| United Therapeutics | 2 |
| Amgen | 1 |
| Artiva Biotherapeutics, Inc. | 1 |
| Bristol-Myers Squibb | 1 |
| CSL Behring | 1 |
| Corbus Pharmaceuticals Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Scleroderma, Diffuse | 39 |
| Scleroderma, Systemic | 24 |
| Lung Diseases, Interstitial | 9 |
| Raynaud Disease | 4 |
| Skin Diseases | 4 |
| Connective Tissue Diseases | 3 |
| Scleroderma, Limited | 3 |
| Arthritis, Rheumatoid | 2 |
| Autoimmune Diseases | 2 |
| Hypertension, Pulmonary | 2 |
Trials
Showing 1 to 25 of 39. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.